Bio-Protocol (Jun 2016)
Hemagglutination Inhibition (HI) Assay of Influenza Viruses with Monoclonal Antibodies
- Ying Wu,
- MyungSam Cho,
- David Shore,
- Manki Song,
- JungAh Choi,
- Tao Jiang,
- Yong-Qiang Deng,
- Melissa Bourgeois,
- Lynn Almli,
- Hua Yang,
- Li-Mei Chen,
- Yi Shi,
- Jianxu Qi,
- An Li,
- Kye Yi,
- MinSeok Chang,
- Jin Bae,
- HyunJoo Lee,
- JiYoung Shin,
- James Stevens,
- SeoungSuh Hong,
- Cheng-Feng Qin,
- George Gao,
- Shin Chang,
- Ruben Donis
Affiliations
- Ying Wu
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- MyungSam Cho
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- David Shore
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Manki Song
- International Vaccine Institute, Seoul, Korea
- JungAh Choi
- International Vaccine Institute, Seoul, Korea
- Tao Jiang
- Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- Yong-Qiang Deng
- Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- Melissa Bourgeois
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Lynn Almli
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Hua Yang
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Li-Mei Chen
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Yi Shi
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaResearch Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China
- Jianxu Qi
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
- An Li
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaCollege of Veterinary Medicine, Guangxi University, Nanning, China
- Kye Yi
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- MinSeok Chang
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- Jin Bae
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- HyunJoo Lee
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- JiYoung Shin
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- James Stevens
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- SeoungSuh Hong
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- Cheng-Feng Qin
- Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- George Gao
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaResearch Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China, Office of Director-General, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
- Shin Chang
- Biotechnology Research Institute, Celltrion, Inc., Incheon, South Korea
- Ruben Donis
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- DOI
- https://doi.org/10.21769/BioProtoc.1828
- Journal volume & issue
-
Vol. 6,
no. 11
Abstract
Heamagglutination is inhibited when antibodies are present because antibodies to the influenza virus will prevent attachment of the virus to red blood cells. The highest dilution of antibody that prevents hemagglutination is called the HI titer. Human monoclonal antibodies generated from single human B cells were tested to characterize their ability to inhibit hemagglutination against virus A/California/07/2009 (H1N1) and A/Brisbane/10/2007 (H3N2).
